Skip to content
Orchid Pharma logo

Orchid Pharma

ORCHPHARMA NSE
₹876.75 +33.50 (+3.97%)
P/E
417.50
View as Markdown
MCP
Close 4 Nov 2026 ₹876.75 +47.00 +5.66% 1Y
Start ₹829.75

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
1.86%
Debt to Equity
0.20
EPS (TTM)
₹2.10
Book Value
₹261.22
Market Cap
—
P/E (TTM)
417.50
P/B
3.36
ROE
1.49%
Dividend Yield
0.00%
EBITDA
₹70.00 Cr
52W High
₹1,143.50
52W Low
₹480.00
Day Range
₹839.10 – ₹880.00
Volume
40,996

Peer Comparison

Healthcare › Pharmaceuticals

Orchid Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Orchid Pharma (this company)
₹876.75417.50₹5,149 Cr3.360.00%1.49%1.86%₹1,073 Cr₹11 Cr
Median 8 companies₹1,587.7058.71₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

35 Poor

Data confidence 100/100

Category scores

Quality
26
Poor
Returns, margins, earnings quality 22% weight
Valuation
17
Poor
Cheap vs sector & own history 24% weight
Growth
44
Weak
Sales & profit trajectory 9% weight
Financial Health
28
Poor
Solvency, leverage, coverage 9% weight
Momentum
50
Average
Trend strength, vol-adjusted 12% weight
Ownership
48
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Promoter holding has increased by 4.61% over last quarter.

Weaknesses

5
  • Stock is trading at 3.02 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 6.76% over last 3 years.
  • Earnings include an other income of Rs.18.6 Cr.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish865
OscillatorsBearish261
Moving AveragesStrong Bearish604

Key readings

RSI (14)
44.21
Neutral
MACD (12,26,9)
−36.67
Bullish
SMA (50)
960.18
Bearish
SMA (200)
813.76
Bullish

As of

Analyst Rating

Based on 1 analysts
HOLD100%

0 of 1 analyst rates Buy, 1 Hold, 0 Sell.

As of

BUY
0
0%
HOLD
1
100%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+3.51%
5Y+22.33%
3Y+22.79%
1Y−11.80%
TTM+14.09%

Net profit

Net profit growth by window
10YTurned to profit
5YTurned to profit
3Y−39.87%
1Y−92.59%
TTM−83.40%

Operating cash flow

Operating cash flow growth by window
10Y−5.07%
5Y+39.33%
3Y+91.29%
1Y+147.06%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−15.70 pp
5Y−2.55 pp
3Y−8.72 pp
1Y−6.91 pp
TTM−4.28 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹797 Cr
Mar 2018₹683 Cr
Mar 2019₹600 Cr
Mar 2020₹484 Cr
Mar 2021₹450 Cr
Mar 2022₹560 Cr
Mar 2023₹666 Cr
Mar 2024₹819 Cr
Mar 2025₹1,398 Cr
Mar 2026₹1,233 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹495 Cr
Mar 2018−₹353 Cr
Mar 2019₹69.00 Cr
Mar 2020−₹131 Cr
Mar 2021−₹117 Cr
Mar 2022−₹2.00 Cr
Mar 2023₹46.00 Cr
Mar 2024₹92.00 Cr
Mar 2025₹135 Cr
Mar 2026₹10.00 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹107 Cr
Reported High Mean Low

Analyst consensus here uses a different definition from reported ebitda (they differ 1.7× on periods where both exist), so the forecast is shown on its own rather than joined to the reported line.

AI Analysis — Bull vs Bear

Generated 31 Jul 2026
AI opinion · based on fundamentals
Risk high

Orchid Pharma Ltd is a mid-cap pharmaceutical company with a market capitalization of ₹5,031 Cr trading at a PE of 246.7x. While the company has shown a 3-year compounded profit growth of 63% and stock CAGR of 21% over 3 years, TTM sales have declined 12% and TTM profit has fallen 73%, with ROE remaining subdued at around 6% over 3 years.

Bull Case 7
  • Strong 3-year compounded profit growth of 63%, indicating meaningful earnings recovery from a low base
  • FY2024 sales reached ₹922 Cr, up 13% year-over-year, and 9M FY25 sales of ₹684 Cr grew 14% vs 9M FY24 (₹602 Cr)
  • 9M FY25 EBITDA improved to ₹115 Cr (17% margin) from ₹99 Cr (16% margin) in 9M FY24, showing margin expansion
  • Low debt-to-equity ratio of approximately 0.12x, indicating a relatively clean balance sheet post-restructuring
  • Stock price CAGR of 38% over 10 years and 21% over 3 years reflects sustained market re-rating
  • 5-year compounded sales growth of 13% shows a medium-term revenue expansion trend
  • 9M FY25 PBT and PAT improved to ₹78 Cr from ₹62 Cr in 9M FY24, a 26% increase on a year-to-date basis
Bear Case 8
  • PE ratio of 246.7x is extremely elevated, implying the stock prices in significant future growth that may not materialize
  • TTM sales declined 12% and TTM profit collapsed 73%, signaling a sharp recent deterioration
  • 3-year average ROE of only 6.41% is low for a pharma company trading at 3.94x book value
  • Company pays zero dividend despite reporting repeated profits, offering no income return to shareholders
  • Earnings quality concern: other income of ₹28.6 Cr forms a significant portion of profits, and company may be capitalizing interest costs
  • 10-year compounded sales growth is negative at -1%, reflecting a long history of revenue stagnation
  • Q3 FY25 standalone sales of ₹217 Cr declined from ₹221 Cr in Q3 FY24, and EBITDA fell to ₹37 Cr from ₹43 Cr, showing quarterly momentum weakening
  • Tax rate appears low, raising questions about the sustainability of reported net profits at current levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

94d ago

TL;DR: Orchid Pharma is executing on international expansion with a meaningful USD 178M Russia licensing deal for Exblifep, while completing the Dhanuka Laboratories merger and actively engaging overseas investors. No visible headwinds in recent news flow. The trend is constructive with the company building commercial partnerships and consolidating its corporate structure.

Positives 1
  • Russia licensing deal for Exblifep Jul 7

    Orchid Pharma signed a licensing pact with Pharmasyntez JSC for Exblifep in Russia, representing a potential USD 178 million opportunity over 10 years.

Neutral 2
  • Dhanuka merger effective, share allotment Jul 10

    Merger with Dhanuka Laboratories became effective on July 10, 2026 after NCLT order filing. Board meeting scheduled Aug 01 to approve equity share allotment to Dhanuka shareholders.

  • Singapore investor roadshow planned Jul 25

    Physical investor roadshow in Singapore scheduled for July 29-31, 2026, led by WTD Mridul Dhanuka with no UPSI to be shared.

Quarterly Results

₹ Cr
ORCHPHARMA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
183
199
221
217
244
223
217
237
263
194
207
368
304
Expenses
161
175
185
188
212
192
191
209
269
195
206
338
290
Operating Profit
22.14
23.3
35.38
28.91
32.49
30.34
26.37
27.99
−5.65
−1.47
1.56
30.16
14
OPM %
12.1%
11.72%
16.04%
13.32%
13.29%
13.62%
12.13%
11.79%
−2.15%
−0.76%
0.75%
8.19%
4.6%
Other Income
1.89
8.36
7.62
13.36
7.57
7.52
8.49
3.9
11.57
10.77
−1.5
7.55
1.83
Interest
5.55
3.8
3.54
3.47
3.5
3.33
3.8
3.92
2.28
3.73
3.18
1.96
2.23
Depreciation
7.71
7.84
9.27
8.42
8.44
8.63
8.61
8.87
10.53
8.9
9.03
10.9
10.95
PBT
10.78
20.02
30.19
30.38
28.12
25.9
22.45
19.1
−6.89
−3.33
−12.15
24.85
2.65
Tax %
0%
0%
0%
−10.27%
−0.53%
0%
0%
−0.21%
0%
0%
0%
0%
2.64%
Net Profit
9.4
19.8
29.43
32.96
29.35
27.24
20.78
22.29
−5.69
−5.72
−12.61
25.84
3.22
EPS (₹)
1.85
3.9
5.8
6.5
5.79
5.37
4.1
4.39
−1.12
−1.13
−2.49
5.09
0.63

Profit & Loss

₹ Cr
ORCHPHARMA profit and loss, annual, ₹ crore
Particulars Mar 2015 18mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,747
873
797
683
600
484
450
560
666
819
1,398
1,233
1,073
Expenses
1,429
703
794
659
612
515
421
505
581
708
1,247
1,185
1,029
Operating Profit
317
171
3
24
−12
−31
29
55
84
111
151
48
44
OPM %
18%
20%
0.4%
3.6%
−2%
−6%
7%
10%
13%
14%
11%
3.9%
4.1%
Other Income
156
−28
−59
20
218
24
15
67
52
31
26
15
19
Interest
537
294
347
310
7
6
52
33
33
17
13
9
11
Depreciation
325
145
141
133
130
118
109
87
55
33
42
43
40
PBT
−389
−296
−544
−399
69
−131
−117
2
48
92
122
10
12
Tax %
−49%
−6%
−9%
−12%
0%
0%
0%
0%
0%
−3%
−8%
−2%
—
Net Profit
−197
−279
−495
−353
69
−131
−117
−2
46
92
135
10
11
EPS (₹)
−23.06
−31.37
−55.69
−39.65
7.8
−32.11
−28.55
−0.48
11.35
18.17
26.63
1.96
2.1
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
ORCHPHARMA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
85
89
89
89
89
41
41
41
41
51
15
15
Reserves
244
−40
−556
−881
−793
725
612
607
648
1,119
1,494
1,504
Borrowings
3,211
3,215
3,106
3,202
3,230
566
453
268
331
135
154
307
Other Liabilities
521
598
616
715
551
128
132
195
205
249
414
432
Total Liabilities
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
2,077
2,258
Fixed Assets
1,795
1,637
1,497
1,386
1,256
858
670
584
573
620
708
692
CWIP
282
280
288
272
278
26
7
10
46
31
81
414
Investments
1
1
1
1
0
0
15
45
44
46
60
67
Other Assets
1,984
1,944
1,470
1,467
1,542
576
544
472
561
857
1,229
1,086
Total Assets
4,061
3,862
3,256
3,125
3,077
1,460
1,237
1,111
1,225
1,554
2,077
2,258

Cash Flow

₹ Cr
ORCHPHARMA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−369
212
401
9
12
81
24
92
18
126
51
126
Investing
1,334
−1
−176
−28
45
167
67
113
−31
−312
−36
−277
Financing
−597
−286
−465
33
0
−250
−165
−217
31
167
2
137
Net Cash Flow
367
−76
−240
15
57
−2
−74
−11
18
−19
17
−14
Free Cash Flow
965
211
392
3
5
77
23
238
−8
61
−102
−255
CFO/EBITDA
−102
124
13,628
67
−138
−226
63
173
22
113
44
259

Ratios

ORCHPHARMA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
54
130
75
64
73
51
110
111
118
87
92
113
Inventory Days
118
220
196
202
214
254
244
201
217
199
187
161
Days Payable
146
341
402
374
381
182
176
195
165
173
137
150
Cash Conversion Cycle
26
9
−130
−108
−94
123
179
117
170
113
142
124
Working Capital Days
−49
−168
−500
−876
−1,158
166
302
97
54
118
101
105
ROCE %
1%
1%
−4%
−4%
−5%
−6%
−5%
−2%
5%
9%
9%
2%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Orchid Pharma insights

72 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 74.45%
  • DIIs 17.44%
  • Public 5.26%
  • Others 1.92%
  • FIIs 0.93%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Orchid Pharma

What does Orchid Pharma Ltd do?
Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.
Where is Orchid Pharma Ltd (ORCHPHARMA) listed?
Orchid Pharma Ltd trades as ORCHPHARMA on the NSE and under code 524372 on the BSE.
Which sector does Orchid Pharma Ltd belong to?
Orchid Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Orchid Pharma Ltd?
Orchid Pharma Ltd trades at a PE ratio of 417.50 as of 4 Nov 2026, on earnings per share of ₹2.1, against a book value of ₹261.22 per share.
What is the 52-week high and low of Orchid Pharma Ltd?
Over the last 52 weeks Orchid Pharma Ltd has traded between ₹480 and ₹1,143.5 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Orchid Pharma Ltd?
Orchid Pharma Ltd reported a return on equity of 1.49%. Its debt-to-equity ratio is 0.20.

Company Information

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.

Website orchidpharma.com
CEO Mr. Manish Dhanuka
Employees 736
Listed 2 Nov 2020
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ORCHPHARMA.md for Orchid Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month